NUVI
Emo Capital Corp.0.0026
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.17MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
8-K
Auditor dismissal after SEC bar
Emo Capital dismissed its auditor BF Borgers effective May 14, 2024, following an SEC order on May 3 permanently barring the firm and its partner for violations. No disagreements or reportable events marred prior audits for fiscal years 2019-2023 or select interims. The company hunts for a replacement. Clean break, but delays could snag filings.
8-K
Board adds ag experts
Emo Capital Corp. added Ming Du and Wei Zhou to its board on January 3, 2023, following court-appointed custodian input, with terms ending at the 2023 annual meeting. Du, ex-CEO of a Chinese agricultural tech firm, will oversee the planned organic fertilizer operations. Zhou, a Florida A&M professor specializing in crop innovation, targets the organic produce venture. This bolsters expertise amid the company's strategic pivot.
10-Q
Q2 FY2017 results
Emo Capital Corp., a development-stage outfit eyeing health and beauty via the web, posted zero revenue and expenses for Q2 FY2017 ended January 31, 2017, matching last year's quiet stretch with no y/y shifts. The six-month YTD mirrored this stasis, holding the cumulative deficit at $92,415 since 2006 inception, while diluted EPS stayed flat at (0.00) across 35.5 million shares. No cash flows stirred, leaving balances at zero amid $60,415 in liabilities from payables and a $13,425 shareholder loan. Officers stand ready to fund via advances. Yet funding shortfalls loom large in this nascent phase.
10-Q
Q3 FY2017 results
Emo Capital Corp., a development-stage outfit eyeing health and beauty via the web, posted zero revenue and expenses for Q3 FY2017 ended April 30, 2017, matching last year's quiet stretch with no y/y shifts. The nine-month YTD net loss held flat at zero, while the lifetime deficit lingers at $92,415 from past fees. No cash on hand, yet liabilities steady at $60,415 including a $13,425 shareholder loan due on demand. Officers stand ready to fund basics. No operations yet. Stagnation suits the dormant phase.
10-Q
Q1 FY2017 results
Emo Capital Corp., a development-stage outfit eyeing health and beauty via the web, posted zero revenue and expenses for Q1 FY2017 ended October 31, 2016, matching last year's quiet quarter while carrying a $92,415 accumulated deficit since 2006 inception. Net loss stayed flat at nil y/y and q/q (derived), with diluted EPS of (0.00) across 35.5 million shares, showing no dilution quirks. Cash balances at zero, propped by a $13,425 interest-free shareholder loan due on demand, alongside $46,990 in payables—management leans on officer advances for survival, flagging going-concern doubts without fresh funding. No free cash flow or non-GAAP metrics disclosed in the 10-Q. Still dormant. Regulatory hurdles could stall web-based product launches.
BIOE
Bio Essence Corp.
0.05+0.00
CANB
CAN B CORP.
0.02+0.00
CPIVF
CAPTIVA VERDE WELLNESS CORP.
0.02-0.00
GEVO
Gevo, Inc.
2.14-0.06
GNVR
Genvor Incorporated
1.70+0.00
NTRR
Neutra Corp.
0.00+0.00
NVVE
Nuvve Holding Corp.
4.07-0.16
NXEN
Nexien BioPharma, Inc.
0.00+0.00
OWPC
One World Products Inc.
0.03+0.01
SNNC
Sibannac, Inc.
0.02-0.00